Matthew J. Shurtleff

This paper introduces cataLYTACs, a new therapeutic modality that efficiently and durably degrades circulating proteins like IgE in vitro and in vivo, outperforming traditional inhibitors.

The paper develops a fluorescent probe to monitor lysosomal catabolism of internalized proteins and applies it to assess therapeutic LYTAC agents.

The paper introduces dynamo, a framework for estimating RNA velocities and predicting cell fates using single-cell RNA-seq data, applied to various biological processes.